Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide

Table 3

Effect of the different sulfonylurea derivatives on ΔHbA1c with respect to TCF7L2 genotypes.

Entire group (𝑛=101)	CC (𝑛=51)	CT (𝑛=41)	TT (𝑛=9)	𝑃	𝑃^adj
ΔHbA1c (%)	1.23±0.11	0.89±0.09	0.85±0.31	0.064	0.022^a
Dominant model	CC (𝑛=51)	CT + TT (𝑛=50)
ΔHbA1c (%)	1.23±0.11	0.88±0.09		0.019	0.006
Group 1 (𝑛=55)	CC (𝑛=28)	CT (𝑛=21)	TT (𝑛=6)
ΔHbA1c (%)	1.32±0.15	0.76±0.10	0.61±0.40	0.010	0.013^b
Dominant model	CC (𝑛=28)	CT + TT (𝑛=27)
ΔHbA1c (%)	1.32±0.15	0.73±0.11		0.003	0.005
Group 2 (𝑛=46)	CC (𝑛=23)	CT (𝑛=20)	TT (𝑛=3)
ΔHbA1c (%)	1.12±0.18	1.01±0.16	1.33±0.39	0.775	0.810
Dominant model	CC (𝑛=23)	CT + TT (𝑛=23)
ΔHbA1c (%)	1.12±0.18	1.06±0.14		0.792	0.783

𝑃 value for ANOVA, 𝑃^adj value adjusted in general linear models for age, gender, baseline HbA1c, baseline BMI, and sulfonylurea dose. Post hoc comparisons between genotype groups: ^aCC versus CT, 𝑃=0.014, CC versus TT, 𝑃=0.06; ^bCC versus CT, 𝑃=0.022, CC versus TT, 𝑃=0.013.